z-logo
open-access-imgOpen Access
SALL 4 induces radioresistance in nasopharyngeal carcinoma via the ATM /Chk2/p53 pathway
Author(s) -
Nie Xin,
Guo Ergang,
Wu Cheng,
Liu Dongbo,
Sun Wei,
Zhang Linli,
Long Guoxian,
Mei Qi,
Wu Kongming,
Xiong Huihua,
Hu Guoqing
Publication year - 2019
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.2056
Subject(s) - radioresistance , nasopharyngeal carcinoma , gene knockdown , apoptosis , radiosensitivity , cancer research , downregulation and upregulation , biology , gene silencing , radiation therapy , cell culture , medicine , genetics , gene
Radiotherapy is the mainstay and primary curative treatment modality in nasopharyngeal carcinoma ( NPC ), whose efficacy is limited by the development of intrinsic and acquired radioresistance. Thus, deciphering new molecular targets and pathways is essential for enhancing the radiosensitivity of NPC . SALL 4 is a vital factor in the development and prognosis of various cancers, but its role in radioresistance remains elusive. This study aimed to explore the association of SALL 4 expression with radioresistance of NPC . It was revealed that SALL 4 expression was closely correlated with advanced T classification of NPC patients. Inhibition of SALL 4 reduced proliferation and sensitized cells to radiation both in vitro and in vivo. Furthermore, SALL 4 silencing increased radiation‐induced DNA damage, apoptosis, and G2/M arrest in CNE 2 and CNE 2R cells. Moreover, knockdown of SALL 4 impaired the expression of p‐ ATM , p‐Chk2, p‐p53, and anti‐apoptosis protein Bcl‐2, while pro‐apoptosis protein was upregulated. These findings indicate that SALL 4 could induce radioresistance via ATM /Chk2/p53 pathway and its downstream proteins related to apoptosis. Targeting SALL 4 might be a promising approach for the development of novel radiosensitizing therapeutic agents for radioresistant NPC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here